Markets Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail XRP Slides to $2.08 as Grayscale’s Markets Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail XRP Slides to $2.08 as Grayscale’s

XRP Slides to $2.08 as Grayscale’s GXRP ETF Debut Fails to Ignite Market

2025/11/24 22:53
6 min read
Share
Share this article
Copy linkX (Twitter)LinkedInFacebookEmail

XRP Slides to $2.08 as Grayscale’s GXRP ETF Debut Fails to Ignite Market

Traders should watch for potential breakdowns below $2.03, which could lead to further declines toward $1.91.

By Shaurya Malwa, CD Analytics
Updated Nov 24, 2025, 2:54 p.m. Published Nov 24, 2025, 2:53 p.m.
(CoinDesk Data)

What to know:

  • Grayscale launched the GXRP ETF on NYSE Arca, expanding institutional access to XRP despite the cryptocurrency's price decline.
  • XRP's price fell from $2.13 to $2.08, with technical factors overshadowing the positive ETF news.
  • Traders should watch for potential breakdowns below $2.03, which could lead to further declines toward $1.91.

Grayscale launches GXRP ETF on NYSE Arca as latest institutional XRP product. XRP falls despite ETF expansion, slipping toward critical psychological support.

News Background

Grayscale expanded its exchange-traded product lineup on Monday with the launch of the Grayscale XRP Trust ETF (GXRP) on NYSE Arca, offering investors direct and “straightforward exposure” to XRP. The product—originally introduced as a private placement in September 2024—was formally converted into a spot ETF as part of Grayscale’s dual listing alongside its new Dogecoin ETF.

STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
Sign me up

Krista Lynch, Senior Vice President of ETF Capital Markets at Grayscale, said GXRP’s listing is “another meaningful step in broadening access to the growing XRP ecosystem,” positioning the fund as an efficient gateway for both institutional and retail investors.

GXRP joins an expanding roster of XRP-based ETFs, including products from Canary Capital and REX Shares, with several more issuers filing under Section 8(a) for automatic approval. The ETF momentum reflects strong institutional appetite for regulated XRP exposure as the asset continues holding its position as the fourth-largest cryptocurrency by market capitalization.

The growing ETF ecosystem emerges despite XRP’s turbulent regulatory past. The U.S. SEC previously accused Ripple of raising $1.3 billion through unregistered XRP sales. A 2023 federal ruling determined that Ripple’s programmatic exchange sales did not violate securities laws due to their blind bid/ask structure, though direct institutional sales were deemed securities offerings. This partial clarity has helped pave the way for broader institutional acceptance—though price action now depends heavily on technical factors rather than purely regulatory developments.

Price Action Summary

XRP declined steadily through Tuesday’s session, slipping from $2.13 to $2.08 as profit-taking and weak spot flows overshadowed the bullish ETF news cycle. The token traded within a volatile range of $2.03 to $2.15, reflecting persistent uncertainty across crypto markets.

• Volume surged 28% above average, hitting 177.9M during the strongest selloff phase
• Price briefly tapped the $2.03 demand zone, rebounding toward $2.11 before stalling
• Multiple failed attempts to reclaim $2.14–$2.15 confirmed resistance dominance
• Late-session selling cracked the $2.10 support floor, turning it into immediate resistance

Despite the ETF expansion and strengthening institutional infrastructure around XRP, the immediate reaction in spot markets showed traders prioritizing technical levels over fundamentals.

Technical Analysis

The breakdown below $2.10 created a new sequence of lower highs and lower lows, confirming the broader short-term downtrend that has been forming since XRP rejected $2.30 earlier in the week.

  • Primary support: $2.03–$2.05 demand zone
  • Immediate resistance: $2.14–$2.15 failure region
  • Mid-term resistance: $2.20–$2.24 cluster
  • Breakdown target: Sub-$2.00 liquidity pocket at $1.91
  • The $2.03 level remains critical. A clean breakdown would expose deeper retracement levels tied to October’s structure.
  • XRP remains in a short-term descending channel
  • Daily timeframe shows sellers defending every retest of $2.15
  • A potential base is forming at $2.03–$2.07 but lacks conviction

Momentum indicators (RSI/MACD) show oversold signals forming, but no trend reversal confirmation has emerged.

What Traders Should Watch

  • A breakdown opens a direct path toward $1.91 and potentially $1.78 if market-wide risk-off intensifies.
  • GXRP and other newly launched ETFs must show sustained inflows, not one-day spikes, for institutional sentiment to translate into spot bid support.
  • This resistance cluster determines whether bulls regain control. Acceptance above here targets $2.20–$2.24.
  • BTC’s renewed weakness directly impacts high-beta tokens like XRP. If Bitcoin continues violating structural support, XRP may not hold $2.00.
  • Whale distribution has slowed—if inflows to exchanges spike again, downside pressure returns immediately.
XRP News

More For You

Protocol Research: GoPlus Security

Commissioned byGoPlus

What to know:

  • As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
  • GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
  • Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
View Full Report

More For You

What Next for DOGE Price as Grayscale's GDOG ETF Debuts?

The $0.1495 resistance level remains a significant barrier, while $0.144 serves as the last short-term support.

What to know:

  • Dogecoin's price fell 1.4% after Grayscale's DOGE ETF debut failed to counteract selling pressure and resistance levels.
  • The $0.1495 resistance level remains a significant barrier, while $0.144 serves as the last short-term support.
  • Institutional demand from the ETF launch will be crucial in determining future price momentum.
Read full story
Latest Crypto News

Monad’s MON Token Stumbles Out of the Gate in Trading Debut After Slow Token Sale

What Next for DOGE Price as Grayscale's GDOG ETF Debuts?

Bitcoin’s $1T Rout Exposes Fragile Market Structure, Deutsche Bank Says

BitMine Immersion Added Nearly 70K Ether Last Week, Now Holding 3% of ETH Supply

CoinDesk 20 Performance Update: Hedera (HBAR) Gains 11.3%, Leading the Index Higher

Monad Blockchain Goes Live With 100B Token Supply and Airdrop

Top Stories

Monad’s MON Token Stumbles Out of the Gate in Trading Debut After Slow Token Sale

BitMine Immersion Added Nearly 70K Ether Last Week, Now Holding 3% of ETH Supply

Bitcoin ETFs, Led by BlackRock's IBIT, See Record $40B Trading Volume as Institutions Capitulate

Upbit Seeking Nasdaq IPO Following Merger With Naver: Bloomberg

Where Next?: Crypto Daybook Americas

DOGE Beats the Blue Chips as D.O.G.E Calls It Quits

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.4563
$1.4563$1.4563
-1.20%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Knocking Bitcoin's lack of yield shows your ‘Western financial privilege’

Knocking Bitcoin's lack of yield shows your ‘Western financial privilege’

                                                                               Macro analyst Luke Gromen’s comments come amid an ongoing debate over whether Bitcoin or Ether is the more attractive long-term option for traditional investors.                     Macro analyst Luke Gromen says the fact that Bitcoin doesn’t natively earn yield isn’t a weakness; it’s what makes it a safer store of value.“If you’re earning a yield, you are taking a risk,” Gromen told Natalie Brunell on the Coin Stories podcast on Wednesday, responding to a question about critics who dismiss Bitcoin (BTC) because they prefer yield-earning assets.“Anyone who says that is showing their Western financial privilege,” he added.Read more
Share
Coinstats2025/09/18 14:22
Ronin Price Prediction 2026-2030: A Strategic Deep Dive into RON’s Critical Juncture

Ronin Price Prediction 2026-2030: A Strategic Deep Dive into RON’s Critical Juncture

BitcoinWorld Ronin Price Prediction 2026-2030: A Strategic Deep Dive into RON’s Critical Juncture As the blockchain gaming sector enters a pivotal phase of maturation
Share
bitcoinworld2026/02/17 19:30
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11